Search AMRX
Amneal Pharmaceuticals, Inc.
Nasdaq · CIK 1723128
Last close20.3
Daily change+0.23 (1.15%)
10 Years gain+35.24%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
AMRX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
59.5Momentum
75.2Acceleration
75.2Confidence
86.0Annual Revenue10
Quarterly Revenue41
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth15.6 / 25
Quality21.4 / 25
Capital Efficiency13.1 / 20
Balance Sheet6.4 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 3.3894 percentage points.
Operating leverageOperating margin improved by 5.0429 percentage points.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM9.75%OK
Revenue CAGR 3Y10.92%OK
Gross Margin40.12%OK
Operating Margin14.97%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC15.87%OK
Incremental Operating Margin 3Y87.85%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y1.28%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $3.02B | $1.11B | $394.10M | $339.99M | $269.93M | 36.88% | 13.05% | 8.94% | 16.52% | 324.81M |
| 2025 FY Dec 31, 2024 | $2.79B | $1.02B | $249.33M | $295.10M | $243.18M | 36.52% | 8.92% | 8.7% | 8.73% | 308.98M |
| 2025 FY Dec 31, 2023 | $2.39B | $820.57M | $204.37M | $345.58M | $302.36M | 34.28% | 8.54% | 12.63% | 6.16% | 176.14M |
| 2024 FY Dec 31, 2022 | $2.21B | $784.71M | -$94.93M | $65.10M | $18.69M | 35.47% | -4.29% | 0.85% | -2.62% | 150.94M |
| 2023 FY Dec 31, 2021 | $2.09B | $768.97M | $152.72M | $241.82M | $194.09M | 36.73% | 7.29% | 9.27% | 3.57% | 151.82M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $3.03B | sum latest 4 fiscal quarters Revenue | OK | 0001723128-26-000031, 0001723128-25-000062 |
| Revenue Growth TTM | 9.75% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001723128-26-000031, 0001723128-25-000062 |
| Revenue CAGR 3Y | 10.92% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001723128-26-000011 |
| Revenue CAGR 5Y | 8.66% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001723128-26-000011 |
| Gross Profit CAGR 3Y | 12.37% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001723128-26-000011 |
| Operating Income Growth | 65.49% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001723128-26-000031, 0001723128-25-000062 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 40.12% | Gross Profit / Revenue | OK | 0001723128-26-000031, 0001723128-25-000062 |
| Operating Margin | 14.97% | Operating Income / Revenue | OK | 0001723128-26-000031, 0001723128-25-000062 |
| ROIC | 15.87% | NOPAT / Average Invested Capital | OK | 0001723128-26-000031, 0001723128-25-000062 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001723128-26-000031 |
| Current Ratio | 2.2x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.05x | (Cash + Short-term Investments) / Total Debt | OK | 0001723128-26-000031 |
| Revenue per Diluted Share | $9.23 | Revenue / Diluted Shares | OK | 0001723128-26-000031, 0001723128-25-000062 |